Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health to Participate in Upcoming Investor Conferences

May 08, 2025 | Last Trade: US$111.57 6.15 5.83

PALO ALTO, Calif. / May 08, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

BofA Securities 2025 Healthcare Conference in Las Vegas, NV
Fireside chat on Wednesday, May 14^th at 3:40 p.m. Pacific Time

Jefferies Global Healthcare Conference in New York, NY
Fireside chat on Wednesday, June 4^th at 2:35 p.m. Eastern Time

Goldman Sachs 46^th Annual Global Healthcare Conference in Miami Beach, FL
Fireside chat on Monday, June 9^th at 10:00 a.m. Eastern Time

Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Stock Quote

Last Trade:	US$111.57
Daily Change:	6.15 5.83
Daily Volume:	2,553,171
Market Cap:	US$14.490B

November 12, 2025 Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access November 10, 2025 Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring November 06, 2025 New Study Validates Guardant Health Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response November 05, 2025 Guardant Health: Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients November 04, 2025 Guardant Health Announces Proposed Public Offering of Common Stock LOAD MORE NEWS

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE